Max Masucci is a Managing Director, Senior Research Analyst al Roth Capital Partners covering life science and diagnostic tools, with a focus on blood-based oncology diagnostics, MRD monitoring, specially tools, and bioprocessing technologies. Prior to joining Roth Capital Partners, Max was a strategy consultant for 908 Devices, where he advised M&A and business development efforts that supported the company's strategic transformation. Max was previously a Managing Director and Senior Research Analyst at Cowen and Canaccord Genuity, where he covered life. science and diagnostic tools.
Max earned a B.S. in Business Administration/Finance (Minor in Italian) from Ithaca College, where he captained the men's basketball team, and holds certificates in Al: Implications for Business Strategy and Al in Healthcare from MIT.
